Overview


According to FutureWise analysis the market for Antiparasitic Drugs in 2023 is US$ 24.76 billion, and is expected to reach US$ 38.93 billion by 2031 at a CAGR of 5.80%.

Antiparasitic are drugs that treat parasitic infections. These drugs work by killing parasites and stopping their growth or paralyzing them. Parasites are microorganisms that live inside or on another organism, referred to as the host organism, and gain benefit at the expense of their host organism. Parasites are responsible for billions of human infections, including malaria. While parasites can include a diverse array of microorganisms, including fungi and bacteria, medically relevant parasites known to cause disease in humans are protozoa, anthelmintics, and ectoparasites. Antiparasitic medications do not work for viral infections such as the common cold and flu. Treatment options vary, depending on the specific causative organism within each class.

Anthelminthic drugs, also known as antiparasitic, act against parasitic worms as either vermicides or vermifuges. Vermicides act by killing the worms, whereas vermifuges help expel the worms, usually in their live state. The ideal anthelminthic drug would have a broad therapeutic index to ensure it is more toxic to the parasitic worm than the host. Anthellminthic drugs can be grouped based on the class of parasitic worms they act on and the drug's chemical structure. Also, Ectoparasites organisms are that live externally on the skin of hosts. They include mites, fleas, ticks, lice, and bedbugs, and they infest the skin and its appendages, causing symptoms such as intense pruritis. Diseases caused by ectoparasites include myiasis, pediculosis, scabies, and trombiculosis.

FutureWise Market Research has published a report that provides an insightful analysis antiparasitic drugs market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry. According to the analysis conducted by FutureWise research analysts antiparasitic drugs market is estimated to register a considerable growth rate over the forecast period. This report lists the market segments and potential prospects available across this industry, in addition providing crucial information on the total valuation currently held by the industry. Moreover, this report will assist key management individuals in an organisation to enhance their decisions pertaining to business expansion as well as strategic changes for increasing customer base.

  • Ipca Laboratories Ltd.
  • Zydus Cadila
  • Merck Kgaa
  • Pfizer
  • Bayer AG.
  • Cipla Ltd.
  • Ranbaxy Laboratories
  • Alvizia Health Care
  • Novartis AG
  • Bayer AG
  • Roche Inc.
  • Arbor Pharmaceuticals Inc.
  • Sanofi
  • AstraZeneca plc
  • Alkem Laboratories Limited

(Note: The list of the major players will be updated with the latest market scenario and trends)

Recent Developments in Antiparasitic Drugs Market:

  • In June 2022, Lyndra Therapeutics dosed the first participant in its Phase I clinical trial investigating oral biweekly ivermectin (LYN-163), an antiparasitic drug, to fight malaria.
  • In March 2022, May & Baker Nigeria PLC launched a new drug, Artelum Combo, to combat malaria parasites nationwide. The medicine is a one-of-a-kind combination of Arthemeter Lumefantrine and Paracetamol that provides complete malaria therapy in a single package.

The rising global incidence of parasitic infections is a significant driver propelling the antiparasitic drugs market. This surge may be attributed to a convergence of influential factors. Firstly, inadequate sanitation practices in certain regions create fertile grounds for the proliferation of parasites, heightening the risk of infections. Also, the increase in international travel, whether for tourism, business, or humanitarian efforts, plays a pivotal role in disseminating these diseases. Travelers may inadvertently carry parasites from endemic regions to non-endemic areas, broadening the infection scope. Moreover, the profound impact of climate change cannot be underestimated. Altered environmental conditions, such as temperature and humidity fluctuations, can create more hospitable environments for parasites and their vectors, further exacerbating the spread of parasitic diseases. Therefore, these factors highlight the need for effective antiparasitic drugs and underscore their essential role in global public health initiatives. Furthermore, the continuous advancements in research and development have fueled the antiparasitic drugs market over the forecast period. This increase in innovation has resulted in the identification and development of antiparasitic drugs that exhibit enhanced efficiency and boast a significantly improved safety profile. This paradigm shift has engendered newfound belief among healthcare professionals, as they now possess a broader arsenal of treatment options at their disposal. These advanced pharmaceuticals target parasites with greater precision and reduce potential side effects, offering patients a more favorable therapeutic experience. However, the emergence of drug resistance among parasites presents a major obstacle in antiparasitic drugs. Over time, parasites have shown an alarming ability to adapt and develop resistance to the very medications designed to combat them. This disturbing trend sabotages the effectiveness of commonly used antiparasitic drugs, causing them to be progressively less potent in their therapeutic impact. This resistance phenomenon significantly complicates treatment procedures, often necessitating the exploration of alternative, potentially less effective drugs or combinations of treatments. Therefore, hindering the growth of antiparasitic drugs in the market.
 

By Drug Class

  • Anthelmintics
    • Benzimidazoles
    • Pyrantel
    • Niclosamide
    • Praziquantel
    • Others
  • Antiprotozoals
    • Antimalarial Drugs
      • Aminoquinolines
      • Quinoline-methanol (4-quinolinemethanols)
      • Cinchona Alkaloids
      • Biguanides
      • Sulfonamides and sulfones
      • Others
    • Other Antiprotozoal Agents
  • Others (Ectoparasites, Pediculocides miticulocides)
    • Lindane
    • Malathion
    • Pyrethrins
    • Others

By Route of Administration

  • Oral
  • Injectable
  • Topical

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

This market research report also emphasis on factors affecting the growth rate in various regions listed above. A deep-down analysis of region will also be provided in the final version of this market which is based on conclusion of primary interviews and secondary data point gathered during the process.

By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. North America registered highest share in the market in 2022. Due to the increasing prevalence of malaria infection, growing awareness, an increasing number of strategic initiatives undertaken by prominent players, the surge in research and development activities, product launches, and increasing migration in the region is expected to fuel the growth of the market. For instance, as per the World Health Organization (WHO), in 2021, more than 723,000 cases of malaria were reported in the United States. Also, according to the data published by the Sepsis Organization in May 2021, toxoplasmosis and Giardia infections are the two most common parasitic infections in North America. Therefore, the above-mentioned factors are anticipated to drive the market growth over the forecast period.

 

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Antiparasitic Drugs Market By Drug Class, By Route of Administration,By Distribution Channel and By Region.
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1 . Years Considered for the Study
         3.2 . Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1 . Secondary Data
          1.1.1 . Key Data from Secondary Sources
         1.2 . Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Global Antiparasitic Drugs Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Antiparasitic Drugs Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Global Antiparasitic Drugs Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Global Antiparasitic Drugs Market, By Drug Class Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Anthelmintics
         1.1. Benzimidazoles
         1.2. Pyrantel
         1.3. Niclosamide
         1.4. Praziquantel
         1.5. Others
        2. Antiprotozoals
         2.1. Antimalarial Drugs
          2.1.1. Aminoquinolines
          2.1.2. Quinoline-methanol (4-quinolinemethanols)
          2.1.3. Cinchona Alkaloids
          2.1.4. Biguanides
          2.1.5. Sulfonamides and sulfones
          2.1.6. Others
         2.2. Other Antiprotozoal Agents
        3. Others (Ectoparasites, Pediculocides
      miticulocides)
         3.1. Lindane
         3.2. Malathion
         3.3. Pyrethrins
         3.4. Others

  • 8.   Global Antiparasitic Drugs Market, By Distribution Channel Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Hospitals Pharmacies
        2. Retail Pharmacies
        3. Online Pharmacies

  • 9.   Global Antiparasitic Drugs Market, By Route of Administration Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Oral
        2. Injectable
        3. Topical

  • 10.   North America Antiparasitic Drugs Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 11.   Latin America Antiparasitic Drugs Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 12.   Europe Antiparasitic Drugs Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 13.   Asia Pacific Antiparasitic Drugs Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 14.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 15.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 16.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Ipca Laboratories Ltd.
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Zydus Cadila
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Merck Kgaa
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Pfizer
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Bayer AG
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Cipla Ltd.
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Ranbaxy Laboratories
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Alvizia Health Care
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Novartis AG
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10.Bayer AG
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview
        11.Roche Inc.
         11.1. Company Overview
         11.2. Product Portfolio
         11.3. SWOT Analysis
         11.4. Financial Overview
         11.5. Strategic Overview
        12.Arbor Pharmaceuticals Inc.
         12.1. Company Overview
         12.2. Product Portfolio
         12.3. SWOT Analysis
         12.4. Financial Overview
         12.5. Strategic Overview
        13.Sanofi
         13.1. Company Overview
         13.2. Product Portfolio
         13.3. SWOT Analysis
         13.4. Financial Overview
         13.5. Strategic Overview
        14.AstraZeneca plc
         14.1. Company Overview
         14.2. Product Portfolio
         14.3. SWOT Analysis
         14.4. Financial Overview
         14.5. Strategic Overview
        15.Alkem Laboratories Limited
         15.1. Company Overview
         15.2. Product Portfolio
         15.3. SWOT Analysis
         15.4. Financial Overview
         15.5. Strategic Overview

  • 17.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by administrations
        5. The overall economic slowdown of the developing and developed nations
  • 18.   FutureWise SME Key Takeaway Points for Client
Partner

Our Clients